Clinical Trial Update: Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms [Phase 2]

View source ↗

Summary

A Phase 2 trial of SJX-653 in postmenopausal women with hot flashes has been terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hot Flashes

Drugs mentioned

• SJX-653

Snippet

Sponsor: Sojournix, Inc. | Conditions: Hot Flashes | Phase 2 | Status: TERMINATED | Results posted: 2022-01-11